Regulation of IL-17 responses during the early phase of arthritis is critical, because serum IL-17 is detectable by day 14 (Figure 1a) and [28] IL-4 secreting DCs administered on day 14 attenuate CIA and suppress in vitro production of IL-17 by T cells [21,23]. The gene discussed is IL17A; the disease is arthritic joint disease.